Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective

Pierre LevyDepartment of Economics and Management of Health Organisations, The University of Paris Dauphine, Paris, FranceView further author information

David M. SmadjaDepartment of Medicine, Paris Descartes University, Sorbonne Paris City, Paris, France;UMR-S1140, Inserm, Paris, France;Hematology Department, AP-HP Georges Pompidou European Hospital, Paris, FranceView further author information

Julie DoreyCreativ Ceutical, Paris, FranceView further author information

Mondher ToumiMedical School, Laboratory of Public Health, The University of the Mediterranean, Marseilles, FranceView further author information

Anna-Katharina MeineckeBayer AG, Berlin, GermanyView further author information

Kevin BowrinBayer Plc, Reading, UKView further author information

Jean-Baptiste BriereBayer AG, Berlin, GermanyCorrespondence[email protected]
View further author information

show all